Feeling contrarian today?
There will be explosive growth in pharmaceuticals, but which one? Look at Idenix Pharmaceuticals.
I'd like to submit Idenix Pharmaceuticals (IDIX) and possibly become the first submitter to be carrying an underperform pick on the same stock in his own profile. The stock is down 26% from my red thumb nearly two years ago, but the S&P is also down 22% and I don't want to close such a longstanding pick without a positive score.
Here's my outperform pitch: After flying almost to 10 in halcyon days before the sun melted its wings, Idenix now trades at an all-time low of 1.84. Novartis declined to license the hepatitis C drug IDX184 despite reasonable proof-of-concept data, and the company has now initiated a phase-two trial without a partner. The stock's continued decline after the Novartis rejection reminds me of a jilted lover, spending a few months in depression before waking up one day and realizing there are other fish in the sea.
The Glaxo deal for the anti-retroviral IDX899 may have also disappointed investors, but Glaxo's assumption of fiscal responsibility for development will help control the burn. The company has $60 million in cash, which will carry it through another year at least, giving it all the time in the world to pull another rabbit out of its hat.
Check out our full portfolio at WallStreetSurvivor
AllStarPortfolio is a community intelligence project from top-rated fools at The Motley Fool.
admin for AllStarPortfolio
Copyright © 2014 Microsoft. All rights reserved.
Serious issues like drought and the deterioration of the developed world spell opportunity for this industry leader.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.